Journey Medical Gelecekteki Büyüme
Future kriter kontrolleri 5/6
Journey Medical kazanç ve gelirinin sırasıyla yıllık 44% ve 26% oranında artması tahmin edilirken, EPS'nin yıllık 43.6% oranında büyümesi bekleniyor.
Anahtar bilgiler
44.0%
Kazanç büyüme oranı
43.57%
EPS büyüme oranı
| Pharmaceuticals kazanç büyümesi | 14.5% |
| Gelir büyüme oranı | 26.0% |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 18 May 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Anlatı Güncellemesi • Apr 27
DERM: Expanded Access And Execution Progress Will Support Future Upside
Narrative Update: Journey Medical Analyst Price Target Shift Analysts have lifted their price target on Journey Medical by $1 to $13.25, citing updated research that supports a higher valuation for the shares. Analyst Commentary Analysts highlighting the move to a US$13.25 price target are framing it as a recalibration based on refreshed research rather than a wholesale shift in the story.Anlatı Güncellemesi • Apr 12
DERM: At The Market Liquidity And Margin Progress Will Support Future Upside
Analysts have raised their price target on Journey Medical by $1 to $13.25, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E to support the new view. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$13.25 price target as better aligned with their updated fair value work, suggesting the prior target did not fully reflect their assumptions on earnings power and risk.
Yeni Anlatı • Apr 10
Slow Reimbursement And Competitive Pressures Will Challenge Dermatology Prescriptions Yet Support Gradual Improvement
Catalysts About Journey Medical Journey Medical focuses on commercializing prescription dermatology treatments, with Emrosi as its flagship oral therapy for inflammatory rosacea lesions. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Mar 28
DERM: At The Market Offering And Margin Progress Will Drive Future Upside
Analysts have adjusted their price target for Journey Medical to $13.25 from $13.50, citing updated views on revenue growth, profit margins, and the stock's future P/E multiple as reflected in recent Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as reflecting confidence that recent revenue trends and cost controls can support the revised P/E assumption used in their models.
Yeni Anlatı • Mar 26
Rosacea Market Tailwinds And Payer Access Will Drive Durable Long Term Dermatology Upside
Catalysts About Journey Medical Journey Medical focuses on commercializing prescription dermatology products, including Emrosi for rosacea, in the U.S. market. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Mar 11
DERM: At The Market Equity Offering Will Support Future Upside Potential
Analysts have maintained their price target for Journey Medical at $13.50, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News Journey Medical filed a follow-on equity offering for its common stock, signaling plans to raise additional capital through the equity market (Key Developments).Anlatı Güncellemesi • Feb 25
DERM: Phase 1 Rosacea Microbiome Safety Will Support Future Upside Potential
Analysts have maintained their price target for Journey Medical at $13.50, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E for the company. What's in the News Journey Medical filed a follow on equity offering for its common stock as an at the market offering, giving the company the option to issue new shares into the market over time (Key Developments).Anlatı Güncellemesi • Feb 10
DERM: Phase 1 Rosacea Microbiome Safety Will Drive Future Upside
Analysts have maintained their price target on Journey Medical at US$13.50, with only slight model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions supporting this stable view. What's in the News Journey Medical filed a follow-on equity offering for its common stock as an at-the-market offering, indicating potential future issuance of additional shares (Key Developments).Anlatı Güncellemesi • Jan 27
DERM: Phase 1 Rosacea Microbiome Safety Will Support Future Upside
Analysts have reaffirmed their price target on Journey Medical at US$13.50, citing unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for keeping their view steady. What's in the News Journey Medical filed a follow-on equity offering for its common stock, structured as an at-the-market offering.Analiz Makalesi • Jan 14
Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Anlatı Güncellemesi • Jan 12
DERM: Phase 3 Rosacea Efficacy And Microbiome Safety Will Drive Upside
Analysts have maintained their price target for Journey Medical at US$13.50. This steady view reflects unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E.Anlatı Güncellemesi • Dec 27
DERM: Phase 3 Rosacea Data And Microbiome Safety Will Support Further Upside
Analysts have modestly reiterated their outlook on Journey Medical, maintaining a price target of $13.50 per share as slight tweaks to the discount rate, revenue growth assumptions, profit margin, and future P E estimates leave their valuation framework effectively unchanged. What's in the News Phase 1 trial results for DFD-29, marketed as Emrosi, showed no detectable impact on skin, gastrointestinal, or vaginal microflora over 16 weeks and confirmed the therapy was well tolerated in healthy adults, supporting its use in moderate to severe rosacea (Key Developments).Anlatı Güncellemesi • Dec 12
DERM: Phase 3 Rosacea Efficacy And Safety Will Likely Support Further Upside
Analysts have modestly reiterated their confidence in Journey Medical, maintaining their price target at 13.50 dollars. Unchanged near term revenue growth, profitability expectations, and valuation multiples continue to support the current fair value outlook.Anlatı Güncellemesi • Nov 28
DERM: Recent Trial Success Will Likely Drive Shares Toward Upside Potential
Analysts have revised their price target for Journey Medical, maintaining it at $13.50 per share. Updates to projected profit margin and future valuation metrics prompted a reassessment of the company's growth outlook.Anlatı Güncellemesi • Nov 14
DERM: Improved Margins and Clinical Results Are Expected to Drive Shares Higher
Analysts have raised their price target for Journey Medical from $11.80 to $13.50. They cite improved profit margin expectations despite slightly adjusted forecasts for revenue growth and discount rates.Analiz Makalesi • Aug 15
US$11.50 - That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After These Results
NasdaqCM:DERM 1 Year Share Price vs Fair Value Explore Journey Medical's Fair Values from the Community and select...Anlatı Güncellemesi • Aug 15
Emrosi Launch Will Expand Rosacea Treatment Options
Journey Medical’s sharply improved net profit margin and lower future P/E ratio signal enhanced profitability and valuation appeal, driving the consensus analyst price target up from $10.50 to $11.50. What's in the News Pharmacy benefit coverage for Emrosi™ increased to 65% of US commercial lives, up from 29% in May.Analiz Makalesi • Aug 12
Is Journey Medical (NASDAQ:DERM) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Apr 01
Is Journey Medical (NASDAQ:DERM) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Yeni Anlatı • Mar 30
Emrosi Launch Will Expand Rosacea Treatment Options
Emrosi's launch and favorable Phase III results are expected to boost revenue growth and enhance net margins through existing operations.Analiz Makalesi • Mar 25
A Piece Of The Puzzle Missing From Journey Medical Corporation's (NASDAQ:DERM) 26% Share Price Climb
Journey Medical Corporation ( NASDAQ:DERM ) shares have continued their recent momentum with a 26% gain in the last...Analiz Makalesi • Feb 06
Journey Medical (NASDAQ:DERM) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Jan 11
Market Cool On Journey Medical Corporation's (NASDAQ:DERM) Revenues Pushing Shares 26% Lower
Unfortunately for some shareholders, the Journey Medical Corporation ( NASDAQ:DERM ) share price has dived 26% in the...Analiz Makalesi • Oct 03
Journey Medical Corporation (NASDAQ:DERM) Shares Fly 31% But Investors Aren't Buying For Growth
Journey Medical Corporation ( NASDAQ:DERM ) shares have had a really impressive month, gaining 31% after a shaky period...Analiz Makalesi • Sep 14
Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • May 06
Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Mar 11
Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%
To the annoyance of some shareholders, Journey Medical Corporation ( NASDAQ:DERM ) shares are down a considerable 31...Analiz Makalesi • Jan 18
Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues
Journey Medical Corporation ( NASDAQ:DERM ) shares have retraced a considerable 33% in the last month, reversing a fair...Analiz Makalesi • Nov 10
Journey Medical Corporation's (NASDAQ:DERM) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Journey Medical Corporation ( NASDAQ:DERM ) shares have continued their recent momentum with a 26% gain in the last...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 198 | 57 | 66 | 47 | 2 |
| 12/31/2027 | 138 | 28 | 42 | 16 | 4 |
| 12/31/2026 | 83 | 1 | 10 | 6 | 4 |
| 3/31/2026 | 65 | -10 | -7 | -7 | N/A |
| 12/31/2025 | 62 | -11 | -12 | -12 | N/A |
| 9/30/2025 | 59 | -9 | -19 | -4 | N/A |
| 6/30/2025 | 56 | -9 | -18 | -3 | N/A |
| 3/31/2025 | 56 | -8 | -22 | -7 | N/A |
| 12/31/2024 | 56 | -15 | -24 | -9 | N/A |
| 9/30/2024 | 58 | -18 | -28 | -28 | N/A |
| 6/30/2024 | 78 | 1 | -8 | -8 | N/A |
| 3/31/2024 | 80 | -4 | 1 | 1 | N/A |
| 12/31/2023 | 79 | -4 | 0 | 5 | N/A |
| 9/30/2023 | 80 | -12 | 13 | 18 | N/A |
| 6/30/2023 | 61 | -39 | -13 | -8 | N/A |
| 3/31/2023 | 63 | -38 | -20 | -15 | N/A |
| 12/31/2022 | 74 | -30 | -34 | -14 | N/A |
| 9/30/2022 | 75 | -41 | -34 | -13 | N/A |
| 6/30/2022 | 79 | -41 | -29 | 1 | N/A |
| 3/31/2022 | 76 | -46 | -33 | -3 | N/A |
| 12/31/2021 | 63 | -44 | -12 | -2 | N/A |
| 9/30/2021 | 59 | -20 | -3 | 6 | N/A |
| 6/30/2021 | 49 | -9 | -3 | -2 | N/A |
| 3/31/2021 | 45 | 4 | 5 | 6 | N/A |
| 12/31/2020 | 45 | 5 | 4 | 5 | N/A |
| 12/31/2019 | 35 | 4 | N/A | 9 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: DERM önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.
Kazançlar ve Piyasa: DERM önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.
Yüksek Büyüme Kazançları: DERM önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.
Gelir ve Pazar: DERM şirketinin gelirinin (yıllık 26% ) US pazarından (yıllık 11.7% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: DERM şirketinin gelirinin (yıllık 26% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: DERM 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 06:18 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Journey Medical Corporation 5 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Scott Henry | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |